As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
Learn more about how MidAtlantic Permanente Medical Group (MAPMG) used Breast IHC AI deployed in HALO AP® to standardize prognostic scores in newly diagnosed breast cancers and increase diagnostic efficiency of first reads.
HALO AP® and Breast IHC AI at MAPMG Read More »
Check out our flyer to learn more about HALO Clinical AI Solutions
HALO Clinical AI Flyer Read More »
Learn more about Indica Labs’ novel CE-IVD certified deep learning clinical workflow for prostate cancer grading.
Novel CE-IVD clinical workflow for analysis of prostate cancer core needle biopsies Read More »
Learn more about Lung Macrodissect AI, an AI-based tool for tumor content quantification and ROI selection guidance.
Learn how Kaiser Permanente deployed Breast IHC AI as a laboratory developed test.
Validation and Clinical Implementation of Breast IHC AI Read More »
Read this white paper to learn about the importance of integration and interoperability in digital pathology and explore examples of how flexible solutions like HALO AP® can enhance workflow efficiency and diagnostic accuracy.
HALO AP Integrations Read More »
Learn more about the automated workflow and benefits of utilizing Lung PD-L1 AI.
Lung PD-L1 AI Brochure Read More »
Learn more about the automated workflow and benefits of CRC Macrodissect AI
CRC Macrodissect AI Brochure Read More »
